Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jun 30, 2021- New labeling approval for Abbott's XIENCE™ stent builds on a legacy of safety and allows for one-month (as short as 28 days) dual anti-platelet therapy (DAPT) for patients at high bleeding risk (HBR)- The new XIENCE Skypoint™ stent received FDA approval in the U.S. and CE Mark approval in Europe- XIENCE stents have 10+ years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent¹ implants-
Jun 7, 2021- First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation- New delivery system works with Abbott's leading Amplatzer Amulet™ LAA Occluder device to enable better access to the LAA and seals off a broad range of LAA anatomies- Steerable sheath gives physicians enhanced flexibility and precise placement when implanting Amplatzer Amulet
-
Jun 7, 2021- All 16 Walgreens locations in the city of Philadelphia will provide the rapid BinaxNOW™ COVID-19 Antigen Self Test at no cost to customers who present a Pennsylvania EBT ACCESS Card, starting June 7 and running through July 4- First-of-its-kind pilot program aims to increase consumer access to rapid testing- BinaxNOW is the most studied and widely available rapid antigen test in the U.S. and has been available nationwide for over-the-counter (OTC), non-prescription purchase at Walgreens since mid-April
- May 17, 2021- Latest-generation TAVI system features advancements to reduce or eliminate risk of blood leakage around valve implant- The non-surgical Navitor TAVI system offers best-in-class deliverability and access through small vessels, expanding treatment options for patients with severe aortic stenosis
- May 6, 2021- A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott's cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure- The trial will utilize Abbott technology including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats- Historically, treating patients with both AFib and heart failure has been challenging, with few effective treatments or options to adequately manage both conditions simultaneously
-
Apr 26, 2021- New imaging platform merges optical coherence tomography (OCT) with the power of automation using artificial intelligence (AI)- Ultreon 1.0 Software helps physicians automatically detect and quantify blood vessel characteristics, giving them better insights for optimal patient treatment- Platform offers advanced imaging features when combined with the Dragonfly OpStar™ imaging catheter used to access complex anatomy
Apr 12, 2021- Abbott, Eliud Kipchoge and the NN Running Team collaborate in a partnership to track glucose levels during training and marathons- Kipchoge and NN Running Team members will wear Abbott's Libre Sense Glucose Sport Biosensor in upcoming competition at the NN Mission Marathon, the fastest way to the Tokyo Games- Built upon the company's world-leading continuous glucose monitoring technology,[i] Abbott's Libre Sense is the world's first glucose biosensor[ii] designed for athletes to help sports performance- Apr 8, 2021- New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve- Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient's complex tricuspid valve anatomy- TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions
- Apr 6, 2021- New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding- XIENCE is the most used drug eluting stent in the world, and European approval for shorter DAPT is supported by two studies that demonstrated safe treatment of stented patients with one-month or three-month use of DAPT- Recent data demonstrate XIENCE with short DAPT does not increase cardiac events and reduces severe bleeding, further confirming the leading safety profile of the XIENCE stent
- Mar 8, 2021- Newly FDA-approved system allows a patient to both communicate with a physician and remotely receive stimulation settings in real time regardless of location*- NeuroSphere Virtual Clinic utilizes advancements made in digital technology to optimize care through intuitive tools that enhance therapy management- Virtual clinic technology can change the treatment approach for patients who live far from necessary medical care or who are burdened by visiting the doctor in person
- Mar 2, 2021- Study of more than 10,000 people identifies a rare group with controlled HIV in the Democratic Republic of Congo, suggesting additional research could uncover links between natural virus suppression and future treatments- Discovery is a result of Abbott's continued virus hunting efforts, which also uncovered a new strain of HIV in 2019- Abbott's decades of work in global viral surveillance has advanced the understanding of HIV and allowed the company to quickly respond to the COVID-19 pandemic with its diagnostic tests
- Jan 14, 2021- New app will allow patients to record their pain relief during the device trial period with spinal cord stimulation or dorsal root ganglion therapy, simplify reporting outcomes and connect patients to physicians who have real-time access to this data- NeuroSphere myPath will be available in the Apple App Store in the coming weeks and will be compatible with the latest iOS operating system
- Dec 22, 2020- 88% of Americans say it's important for COVID-19 testing to work in support of vaccine rollout- Americans agree an authorized vaccine will not change the environment overnight, indicating a need for ongoing layered protections- Despite belief in effectiveness of vaccination and testing, there is concern that other precautionary measures will decline
-
Dec 9, 2020Virtual reality training improved cath lab staff learning engagement by 45% and knowledge retention by 72%87% of studies show higher medical accuracy in medical practice by those trained with virtual reality
- Oct 30, 2020-- Considered as the industry's equivalent of the Nobel Prize in biopharmaceutical and medical technology research, Prix Galien USA honored MitraClip as the Best Medical Technology for 2020-- The groundbreaking MitraClip therapy has positively impacted the lives of more than 100,000 people globally living with mitral regurgitation, or a leaky heart valve
- Oct 19, 2020- New research from the University of Illinois, Urbana-Champaign, Abbott, and U.S. Air Force published in the journal Scientific Reports demonstrates that the right nutrition is directly linked to physical and cognitive performance in active duty men and women in the U.S. Air Force- Research subjects from the U.S. Air Force, who consumed a specialized nutrition drink with key nutrients, showed an 11% improvement in working memory, resulting in better information processing, problem-solving and multitasking skills- When nutrition was combined with an exercise regimen, study participants showed statistically significant improvements in 80% of key fitness and cognition metrics measured
-
Sep 30, 2020- Low back pain affects one in 10 Americans and often impacts the patient physically, emotionally and economically- The multicenter, randomized, controlled DISTINCT study represents an Abbott collaboration with both spine surgeons and pain specialists to amass post-market evidence for its BurstDR™ spinal cord stimulation therapy for patients who have limited surgical options
- Sep 3, 2020- The LIFE-BTK trial will evaluate the company's new drug-eluting resorbable scaffold (DRS), known as the Esprit BTK System, for the treatment of blocked arteries below-the-knee (BTK)- Esprit BTK was granted breakthrough device designation by the U.S. FDA- There are no stents or drug-coated balloons currently approved for use below the knee in the U.S.
- Jul 23, 2020- Apple‡ smartphone-compatible digital health tool fits within the company's broader NeuroSphere™ Digital Care connected care management platform, which is designed to optimize care for chronic pain and movement disorders- NeuroSphere Digital Care offers flexible virtual care options as the COVID-19 global pandemic impacts how healthcare is administered- Approval of the Patient Controller app is the latest launch under the NeuroSphere Digital Care(1) platform
- Jul 6, 2020- Next-generation Gallant™ implantable cardioverter defibrillator family of devices offers Bluetooth® capability for a more meaningful connection between patients and their doctors- Gallant ICD and CRT-D devices feature a patient-preferred design without compromising on battery longevity and compatibility with magnetic resonance imaging (MRI)
- Jun 26, 2020-- Using optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI), physicians were able to select the right size stents and place them with greater precision-- Imaging techniques such as OCT have been shown to improve outcomes during stenting procedures¹, but remain underutilized in global clinical settings due to lack of awareness-- OCT is a high-resolution, infrared light-based imaging technique that provides unparalleled accuracy for physicians during stent implantation
- Jun 25, 2020- New data reinforce Abbott's leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies- Eleven late-breaking presentations at the PCR e-Course showcase impact of Abbott's innovative structural heart portfolio on patient outcomes and quality of life in real-world and clinical settings
- May 21, 2020- Abbott's antibody test to be deployed as part of the UK Secretary of State for Health's initiative for highly-reliable, large-scale antibody testing- European-made blood test will run on Abbott's ARCHITECT® i1000SR and i2000SR, as well as its Alinity™ i laboratory instruments- 800,000 Abbott tests have already been delivered to NHS laboratories across the UK- Test demonstrated reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days or more after symptoms started
- May 12, 2020Abbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity™ m System- Alinity m is Abbott's new molecular lab system, which was approved by the U.S. FDA in March- The Alinity m system is highly advanced and greatly improves speed and efficiency, running up to 1,080 tests in 24 hours- Abbott is launching Alinity m to U.S. customers and will be making the SARS-CoV-2 test available for use under an Emergency Use Authorization- This is Abbott's fifth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic
- May 11, 2020- Data shows reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days after symptoms began- Abbott plans to ship nearly 30 million antibody tests globally in May across its ARCHITECT and Alinity i platforms and will have capacity for 60 million in June- Abbott expects to submit for CE Mark for its Alinity i SARS-CoV-2 IgG test this week and will initiate global shipments immediately- This is Abbott's fourth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic
- Apr 9, 2020- CE Mark for TriClip represents an important treatment option for people with severe tricuspid regurgitation, a difficult-to-manage heart condition- New system offers a proven safe and effective minimally invasive non-surgical solution- The TriClip System leverages Abbott's proven clip-based technology used in its MitraClip™ transcatheter mitral valve therapy
Apr 8, 2020-- More than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized, according to a report from the Centers for Disease Control and Prevention (CDC)¹-- FreeStyle Libre 14 day system can be used by frontline healthcare workers in hospitals to remotely monitor patients with diabetes who can scan² to minimize exposure to COVID-19 and preserve use of personal protective equipment (PPE)-- In partnership with the American Diabetes Association (ADA), Abbott will donate 25,000 FreeStyle Libre 14 day sensors to U.S. hospitals and medical centers in outbreak hotspots to help accelerate access to technology
Mar 27, 2020- The Abbott ID NOW™ COVID-19 test brings rapid testing to the front lines- Test to run on Abbott's point-of-care ID NOW platform - a portable instrument that can be deployed where testing is needed most- ID NOW has the largest molecular point-of-care installed base in the U.S. and is available in a wide range of healthcare settings- Abbott will be making ID NOW COVID-19 tests available next week and expects to ramp up manufacturing to deliver 50,000 tests per day- This is the company's second test to receive Emergency Use Authorization by the FDA for COVID-19 detection; combined, Abbott expects to produce about 5 million tests per month- Feb 20, 2020- Data at ATTD reinforce and add to a growing body of clinical research and real-world evidence from users of the FreeStyle Libre system around the world- People in Germany living with Type 1 or Type 2 diabetes on insulin showed a sustained reduction in HbA1c over one year following use of the FreeStyle Libre technology
Feb 19, 2020- Collaboration will combine Abbott's leading continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform- Integrated technology will provide people living with diabetes around the world an affordable, transformational experience for improved glucose control- Jan 30, 2020- First-of-its-kind technology addresses critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option- Tendyne valve provides relief from heart failure symptoms and quality-of-life improvement in high-surgical-risk patients- Together with MitraClip™, Tendyne expands Abbott's market-leading portfolio of innovative minimally invasive mitral valve solutions
- Nov 6, 2019- Discovery marks the first time a new subtype of HIV-1 has been identified since 2000- Abbott is making this new strain accessible to the research community to evaluate its impact to diagnostic testing, treatments and potential vaccines
-
Oct 22, 2019- One-third of Americans have heard someone say: "I drive better when I've smoked marijuana"- While drunk driving is on the decline, drug-impaired driving is on the rise[1]- Eleven states and Washington, DC, have legalized marijuana for recreational use; Illinois, Michigan are two of the next states to begin adult-use sales in 2020
- Oct 15, 2019- Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes
-
Oct 15, 2019-- Oct. 17, 2019, marks the one-year anniversary of legalized recreational cannabis nationwide-- A year after legalization, 71% of Canadians are concerned about its impact on road safety-- Survey shows Canadians want more to be done to keep roads safe
Oct 14, 2019- Collaboration combines Abbott′s world-leading glucose sensing technology with Omada Health's best-in-class, proprietary digital coaching platform to provide personalized, on-the-go care- As part of Omada's expanded Type 2 diabetes offering, FreeStyle Libre will be the exclusive CGM delivered directly to participants' doorsteps - expanding access to the technology for more people with diabetes- Sep 26, 2019- Proclaim™ XR neurostimulation system uses Abbott's proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years*- More than 50 million people in the United States are affected by chronic pain- Abbott's low-dose and low-energy pain management technology is designed to provide pain relief and improve system longevity, offering patients a life-altering option for pain relief without the hassles of recharging
- Sep 25, 2019Newly cleared diagnostic test could help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women
- Sep 16, 2019- Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin- Two world leaders in diabetes work together to drive meaningful change in care
- Sep 10, 2019- New research found Abbott's algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis- This technology is the first machine learning developed algorithm that combines high sensitive troponin testing with other patient details to help doctors better determine if a heart attack is occurring
- Aug 26, 2019- The TRACK-TBI study found that 64% of people with the highest levels of a protein in the blood were confirmed to have brain injury through an MRI scan, even when a CT scan did not detect it- Abbott's diagnostic test, currently in development, is poised to be the first point-of-care blood test for assessing concussions on its next generation i-STAT™ device, providing doctors results in 15 minutes
- Aug 14, 2019- Agreement gives law enforcement access to the most advanced handheld tools to help detect drug and alcohol-impaired drivers- Collaboration is a major step in keeping roads safer as recreational marijuana legalization accelerates[1]
- Jul 15, 2019- U.S. approval for MitraClip G4 offers a next-generation approach to mitral valve repair- G4 includes new clip sizes and an enhanced leaflet grasping feature
- May 21, 2019- Late-breaking data for Abbott's investigational clip-based tricuspid heart valve repair system presented at EuroPCR- Data suggest the first-of-its-kind device reduces difficult-to-treat tricuspid regurgitation at 30 days- Study builds upon Abbott's success with its proven MitraClip™ clip-based technology in treating a similar disease on the left side of the heart
- May 14, 2019- Partnership with NIH aims to increase understanding and accelerate the application of neurostimulation therapies- The BRAIN Initiative brings together the brightest minds across disciplines to improve the treatment and prevention of brain disorders
- Apr 29, 2019- Research found Abbott's High-Sensitive Troponin-I blood test may identify adults at risk of having a cardiac event, independent of other heart disease risk factors- Abbott's core laboratory diagnostic test is the first troponin blood test with CE Mark that can more accurately predict risk of developing heart disease, when added to other heart disease risk assessments, than using other assessments alone
- Mar 14, 2019- The world's first minimally invasive mitral valve repair device now approved to help difficult-to-treat heart failure patients with clinically significant secondary mitral regurgitation- Approval is based on groundbreaking pivotal data from the COAPT™ Trial- New indication significantly expands number of people with mitral regurgitation that can be treated with the MitraClip device
- Feb 20, 2019Collaboration will enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible(i) with FreeStyle Libre portfolio of products